PerkinElmer, Inc. (NYSE:PKI) has earned an average recommendation of “Hold” from the sixteen research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, eleven have given a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $78.36.

Several analysts have commented on the company. Zacks Investment Research upgraded PerkinElmer from a “hold” rating to a “buy” rating and set a $85.00 target price on the stock in a research note on Thursday, May 24th. Bank of America dropped their price target on PerkinElmer from $86.00 to $83.00 and set a “hold” rating on the stock in a research note on Tuesday, May 1st. Morgan Stanley dropped their price target on PerkinElmer from $89.00 to $85.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 11th. Robert W. Baird dropped their price target on PerkinElmer from $88.00 to $82.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 1st. Finally, Janney Montgomery Scott dropped their price target on PerkinElmer from $92.00 to $73.36 and set a “fair value” rating on the stock in a research note on Tuesday, May 1st.

PKI traded up $0.12 during trading on Tuesday, hitting $75.67. 680,109 shares of the company’s stock traded hands, compared to its average volume of 587,439. The company has a current ratio of 1.33, a quick ratio of 0.93 and a debt-to-equity ratio of 0.73. PerkinElmer has a 12-month low of $62.43 and a 12-month high of $84.49. The company has a market cap of $8.37 billion, a price-to-earnings ratio of 25.22, a P/E/G ratio of 1.74 and a beta of 0.86.

PerkinElmer (NYSE:PKI) last issued its earnings results on Monday, April 30th. The medical research company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.61 by $0.02. PerkinElmer had a return on equity of 13.26% and a net margin of 11.73%. The business had revenue of $644.00 million for the quarter, compared to the consensus estimate of $618.97 million. During the same period last year, the business posted $0.55 EPS. The company’s revenue was up 0 compared to the same quarter last year. research analysts forecast that PerkinElmer will post 3.61 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, August 10th. Investors of record on Friday, July 20th will be issued a $0.07 dividend. The ex-dividend date is Thursday, July 19th. This represents a $0.28 dividend on an annualized basis and a yield of 0.37%. PerkinElmer’s dividend payout ratio is currently 9.66%.

In related news, Director Nicholas A. Lopardo sold 4,000 shares of the firm’s stock in a transaction on Friday, May 25th. The stock was sold at an average price of $74.92, for a total value of $299,680.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Daniel R. Tereau sold 1,156 shares of the firm’s stock in a transaction on Wednesday, April 18th. The stock was sold at an average price of $77.00, for a total value of $89,012.00. Following the completion of the transaction, the insider now directly owns 6,784 shares in the company, valued at $522,368. The disclosure for this sale can be found here. 2.10% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of the business. Thrivent Financial for Lutherans raised its holdings in PerkinElmer by 0.3% during the first quarter. Thrivent Financial for Lutherans now owns 279,809 shares of the medical research company’s stock valued at $21,187,000 after acquiring an additional 700 shares during the period. Envestnet Asset Management Inc. grew its position in shares of PerkinElmer by 17.0% during the fourth quarter. Envestnet Asset Management Inc. now owns 5,016 shares of the medical research company’s stock valued at $367,000 after purchasing an additional 729 shares in the last quarter. Commonwealth Equity Services LLC grew its position in shares of PerkinElmer by 8.0% during the first quarter. Commonwealth Equity Services LLC now owns 9,838 shares of the medical research company’s stock valued at $744,000 after purchasing an additional 730 shares in the last quarter. Virginia Retirement Systems ET AL grew its position in shares of PerkinElmer by 12.3% during the first quarter. Virginia Retirement Systems ET AL now owns 8,200 shares of the medical research company’s stock valued at $621,000 after purchasing an additional 900 shares in the last quarter. Finally, Hudson Valley Investment Advisors Inc. ADV grew its position in shares of PerkinElmer by 6.4% during the second quarter. Hudson Valley Investment Advisors Inc. ADV now owns 15,442 shares of the medical research company’s stock valued at $1,131,000 after purchasing an additional 935 shares in the last quarter. 93.58% of the stock is currently owned by institutional investors and hedge funds.

PerkinElmer Company Profile

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil.

Featured Story: Do closed-end mutual funds pay dividends?

Analyst Recommendations for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.